Many small biotechs in the U.S. and Europe do not have the resources to develop their programs in China in parallel with Western territories, leading to a five- to eight-year lag before a Chinese launch. CANbridge Life Sciences Ltd. plans to in-license candidates from these companies for China and elsewhere in East Asia as part of a global development strategy for its biotech partners.

CANbridge wants to get the programs to patients in China faster and believes its executive team can help small biotechs develop their programs in China in parallel with an in-house Western development program.